Mitsuhito Sasaki

2PUBLICATIONS
17CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

Sort by Publication Date:
|Aug 05, 2024
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial.

Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto

|Aug 09, 2021
A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.

Mitsuhito Sasaki, Hideki Ueno, Shuichi Mitsunaga

Pageof 1

Frequent Collaborators

1 joint publications

Akihiro Ohba

1 joint publications

Chigusa Morizane

1 joint publications

Yasuyuki Kawamoto

1 joint publications

Yoshito Komatsu

1 joint publications

Makoto Ueno

1 joint publications

Satoshi Kobayashi

1 joint publications

Masafumi Ikeda

1 joint publications

Junji Furuse

1 joint publications

Naohiro Okano

1 joint publications

Hiroshi Yoshida

Frequent Collaborators

1 joint publications

Akihiro Ohba

1 joint publications

Chigusa Morizane

1 joint publications

Yasuyuki Kawamoto

1 joint publications

Yoshito Komatsu

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on : Aug 18, 2023

1.9K
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on : Jul 31, 2016

12.1K
See more related videos

Top Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on : Aug 18, 2023

1.9K
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on : Jul 31, 2016

12.1K
See more related videos